Swedish listed oncology research company looking for resourceful partner for out-licensing/ possible acquisition of assets. The most advanced asset is a post phaseII drug candidate for treatment of advanced prostate cancer.
For more information please contact;
Dr. Odilo Mueller
CYTO Consulting, LLC
Tel.: +1 339 707 0767